Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation.

Beulque Y, Deleu AL, Punie K, De Wever L, Baldewijns M, Caruso S, Couchy G, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e909-e912. doi: 10.1016/j.clgc.2019.06.013. Epub 2019 Jul 11. No abstract available.

PMID:
31378579
2.

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.

Roldan-Romero JM, Beuselinck B, Santos M, Rodriguez-Moreno JF, Lanillos J, Calsina B, Gutierrez A, Tang K, Lainez N, Puente J, Castellano D, Esteban E, Climent MA, Arranz JA, Albersen M, Oudard S, Couchy G, Caleiras E, Montero-Conde C, Cascón A, Robledo M, Rodríguez-Antona C, García-Donas J; Spanish Oncology Genitourinary Group (SOGUG).

Int J Cancer. 2019 Jul 23. doi: 10.1002/ijc.32579. [Epub ahead of print]

PMID:
31335987
3.

Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Oct;17(5):e981-e994. doi: 10.1016/j.clgc.2019.05.009. Epub 2019 May 25.

PMID:
31229459
4.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.

Nault JC, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie-Bergman C, Ziol M, Bioulac-Sage P, Couchy G, Blanc JF, Nahon P, Amaddeo G, Ganne-Carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman-Rossi J.

Hepatology. 2019 Jun 17. doi: 10.1002/hep.30811. [Epub ahead of print]

PMID:
31206197
5.

Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.

Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S.

Gastroenterology. 2019 Sep;157(3):760-776. doi: 10.1053/j.gastro.2019.05.001. Epub 2019 May 4.

PMID:
31063779
6.

Polyploidy spectrum: a new marker in HCC classification.

Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, Albuquerque M, Couchy G, Paradis V, Couty JP, Zucman-Rossi J, Desdouets C.

Gut. 2019 Apr 12. pii: gutjnl-2018-318021. doi: 10.1136/gutjnl-2018-318021. [Epub ahead of print]

7.

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma.

Gérard C, Di-Luoffo M, Gonay L, Caruso S, Couchy G, Loriot A, Castven D, Tao J, Konobrocka K, Cordi S, Monga SP, Hanert E, Marquardt JU, Zucman-Rossi J, Lemaigre FP.

J Hepatol. 2019 Aug;71(2):323-332. doi: 10.1016/j.jhep.2019.03.024. Epub 2019 Apr 4.

PMID:
30953666
8.

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.

Bayard Q, Meunier L, Peneau C, Renault V, Shinde J, Nault JC, Mami I, Couchy G, Amaddeo G, Tubacher E, Bacq D, Meyer V, La Bella T, Debaillon-Vesque A, Bioulac-Sage P, Seror O, Blanc JF, Calderaro J, Deleuze JF, Imbeaud S, Zucman-Rossi J, Letouzé E.

Nat Commun. 2018 Dec 7;9(1):5235. doi: 10.1038/s41467-018-07552-9.

9.

Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib.

Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schöffski P, Dumez H, Debruyne PR, Lerut E, Machiels JP, Richard V, Albersen M, Verschaeve V, Oudard S, Méjean A, Wolter P, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2019 Apr;17(2):e235-e246. doi: 10.1016/j.clgc.2018.11.002. Epub 2018 Nov 16.

PMID:
30527746
10.

Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma.

L'Hermitte A, Pham S, Cadoux M, Couchy G, Caruso S, Anson M, Crain-Denoyelle AM, Celton-Morizur S, Yamagoe S, Zucman-Rossi J, Desdouets C, Couty JP.

Hepatology. 2019 Jan;69(1):160-178. doi: 10.1002/hep.30140. Epub 2018 Dec 22.

PMID:
30070727
11.

Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.

Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J.

Hepatology. 2018 Sep;68(3):964-976. doi: 10.1002/hep.29884. Epub 2018 Jun 6.

PMID:
29572896
12.

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Verbiest A, Lambrechts D, Van Brussel T, Couchy G, Wozniak A, Méjean A, Lerut E, Oudard S, Verkarre V, Job S, de Reynies A, Machiels JP, Patard JJ, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2018 Aug;16(4):266-273. doi: 10.1016/j.clgc.2018.01.013. Epub 2018 Feb 5.

PMID:
29503246
13.

Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.

Verbiest A, Couchy G, Job S, Caruana L, Lerut E, Oyen R, de Reyniès A, Tosco L, Joniau S, Van Poppel H, Van Raemdonck D, Van Den Eynde K, Wozniak A, Zucman-Rossi J, Beuselinck B.

Eur Urol. 2018 Oct;74(4):474-480. doi: 10.1016/j.eururo.2018.01.042. Epub 2018 Feb 17.

PMID:
29463434
14.

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.

Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B.

Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612. doi: 10.1016/j.clgc.2017.10.017. Epub 2017 Nov 7.

PMID:
29239846
15.

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.

Letouzé E, Shinde J, Renault V, Couchy G, Blanc JF, Tubacher E, Bayard Q, Bacq D, Meyer V, Semhoun J, Bioulac-Sage P, Prévôt S, Azoulay D, Paradis V, Imbeaud S, Deleuze JF, Zucman-Rossi J.

Nat Commun. 2017 Nov 3;8(1):1315. doi: 10.1038/s41467-017-01358-x.

16.

Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.

Beuselinck B, Verbiest A, Couchy G, Job S, de Reynies A, Meiller C, Albersen M, Verkarre V, Lerut E, Méjean A, Patard JJ, Laguerre B, Rioux-Leclercq N, Schöffski P, Oudard S, Zucman-Rossi J.

Acta Oncol. 2018 Apr;57(4):498-508. doi: 10.1080/0284186X.2017.1388927. Epub 2017 Nov 2.

PMID:
29095068
17.

Focal β-catenin mutation identified on formalin-fixed and paraffin-embedded inflammatory hepatocellular adenomas.

Saldarriaga J, Bisig B, Couchy G, Castain C, Zucman-Rossi J, Balabaud C, Sempoux C, Bioulac-Sage P.

Histopathology. 2017 Dec;71(6):989-993. doi: 10.1111/his.13283. Epub 2017 Oct 6.

PMID:
28618047
18.

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.

Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J.

J Hepatol. 2017 Oct;67(4):727-738. doi: 10.1016/j.jhep.2017.05.014. Epub 2017 May 19.

PMID:
28532995
19.

Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription.

Patitucci C, Couchy G, Bagattin A, Cañeque T, de Reyniès A, Scoazec JY, Rodriguez R, Pontoglio M, Zucman-Rossi J, Pende M, Panasyuk G.

J Clin Invest. 2017 May 1;127(5):1873-1888. doi: 10.1172/JCI90327. Epub 2017 Apr 10.

20.

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro.

Rebouissou S, La Bella T, Rekik S, Imbeaud S, Calatayud AL, Rohr-Udilova N, Martin Y, Couchy G, Bioulac-Sage P, Grasl-Kraupp B, de Koning L, Ganne-Carrié N, Nault JC, Ziol M, Zucman-Rossi J.

Clin Cancer Res. 2017 Aug 1;23(15):4364-4375. doi: 10.1158/1078-0432.CCR-16-3118. Epub 2017 Feb 28.

21.

Germline and somatic DICER1 mutations in familial and sporadic liver tumors.

Caruso S, Calderaro J, Letouzé E, Nault JC, Couchy G, Boulai A, Luciani A, Zafrani ES, Bioulac-Sage P, Seror O, Imbeaud S, Zucman-Rossi J.

J Hepatol. 2017 Apr;66(4):734-742. doi: 10.1016/j.jhep.2016.12.010. Epub 2016 Dec 22.

PMID:
28012864
22.

Metalloproteinase meprin α regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin.

Breig O, Yates M, Neaud V, Couchy G, Grigoletto A, Lucchesi C, Prox J, Zucman-Rossi J, Becker-Pauly C, Rosenbaum J.

Oncotarget. 2017 Jan 31;8(5):7839-7851. doi: 10.18632/oncotarget.13975.

23.

Malignant transformation of a β-catenin inflammatory adenoma due to an S45 β-catenin-activating mutation present 12 years before.

Sempoux C, Bisig B, Couchy G, Balabaud C, Zucman-Rossi J, Bioulac-Sage P.

Hum Pathol. 2017 Apr;62:122-125. doi: 10.1016/j.humpath.2016.10.004. Epub 2016 Oct 28.

PMID:
27984126
24.

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.

Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators, Bioulac-Sage P, Letouzé E, Zucman-Rossi J.

Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7.

25.

The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.

Simerzin A, Zorde-Khvalevsky E, Rivkin M, Adar R, Zucman-Rossi J, Couchy G, Roskams T, Govaere O, Oren M, Giladi H, Galun E.

Hepatology. 2016 Nov;64(5):1623-1636. doi: 10.1002/hep.28679. Epub 2016 Jul 25.

PMID:
27302319
26.

Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin.

Tao J, Xu E, Zhao Y, Singh S, Li X, Couchy G, Chen X, Zucman-Rossi J, Chikina M, Monga SP.

Hepatology. 2016 Nov;64(5):1587-1605. doi: 10.1002/hep.28601. Epub 2016 May 28.

27.

TGF-β1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking.

Ezzoukhry Z, Henriet E, Piquet L, Boyé K, Bioulac-Sage P, Balabaud C, Couchy G, Zucman-Rossi J, Moreau V, Saltel F.

Eur J Cell Biol. 2016 Nov;95(11):503-512. doi: 10.1016/j.ejcb.2016.09.003. Epub 2016 Oct 4.

PMID:
27720259
28.

Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.

Beuselinck B, Jean-Baptiste J, Schöffski P, Couchy G, Meiller C, Rolland F, Allory Y, Joniau S, Verkarre V, Elaidi R, Lerut E, Roskams T, Patard JJ, Oudard S, Méjean A, Lambrechts D, Zucman-Rossi J.

BJU Int. 2016 Dec;118(6):890-901. doi: 10.1111/bju.13585. Epub 2016 Aug 12.

29.

Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.

Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault JC, Couchy G, Laurent A, Balabaud C, Bioulac-Sage P, Zucman-Rossi J.

Hepatology. 2016 Dec;64(6):2047-2061. doi: 10.1002/hep.28638. Epub 2016 Jun 11.

PMID:
27177928
30.

Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease.

Guldiken N, Kobazi Ensari G, Lahiri P, Couchy G, Preisinger C, Liedtke C, Zimmermann HW, Ziol M, Boor P, Zucman-Rossi J, Trautwein C, Strnad P.

J Hepatol. 2016 Sep;65(3):552-9. doi: 10.1016/j.jhep.2016.04.024. Epub 2016 May 2.

PMID:
27151178
31.

Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV.

Nault JC, Mami I, La Bella T, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Mol Ther. 2016 Apr;24(4):660-1. doi: 10.1038/mt.2016.47. No abstract available.

32.

AAV2 and Hepatocellular Carcinoma.

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Hum Gene Ther. 2016 Mar;27(3):211-3. doi: 10.1089/hum.2016.002. No abstract available.

PMID:
26935016
33.

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs.

Beuselinck B, Jean-Baptiste J, Couchy G, Job S, De Reynies A, Wolter P, Théodore C, Gravis G, Rousseau B, Albiges L, Joniau S, Verkarre V, Lerut E, Patard JJ, Schöffski P, Méjean A, Elaidi R, Oudard S, Zucman-Rossi J.

Br J Cancer. 2015 Nov 3;113(9):1313-22. doi: 10.1038/bjc.2015.352. Epub 2015 Oct 13.

34.

Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.

Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-Paul MC, Azoulay D, Mehdaoui D, Luciani A, Zafrani ES, Bioulac-Sage P, Zucman-Rossi J.

Mod Pathol. 2016 Jan;29(1):43-50. doi: 10.1038/modpathol.2015.119. Epub 2015 Oct 30.

35.

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.

Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J.

Nat Genet. 2015 Oct;47(10):1187-93. doi: 10.1038/ng.3389. Epub 2015 Aug 24.

PMID:
26301494
36.

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.

Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J.

Nat Genet. 2015 May;47(5):505-511. doi: 10.1038/ng.3252. Epub 2015 Mar 30.

37.

Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.

Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J.

Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12.

38.

Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.

Beuselinck B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.

Acta Oncol. 2014 Oct;53(10):1413-22. doi: 10.3109/0284186X.2014.918276. Epub 2014 May 30.

PMID:
24874929
39.

Characterization of a novel PXR isoform with potential dominant-negative properties.

Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, Evrard A, Kantar J, Chevet E, Bioulac-Sage P, Ramos J, Assenat E, Joubert D, Pannequin J, Hollande F, Pascussi JM.

J Hepatol. 2014 Sep;61(3):609-16. doi: 10.1016/j.jhep.2014.04.030. Epub 2014 May 2.

PMID:
24798619
40.

Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.

Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G, Mallet M, Taouji S, Balabaud C, Terris B, Canal F, Paradis V, Scoazec JY, de Muret A, Guettier C, Bioulac-Sage P, Chevet E, Calvo F, Zucman-Rossi J.

Cancer Cell. 2014 Apr 14;25(4):428-41. doi: 10.1016/j.ccr.2014.03.005.

41.

Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma.

Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, Paradis V, Leteurtre E, Sturm N, Ramos J, Guettier C, Bardier-Dupas A, Boulai A, Wendum D, Selves J, Izard T, Nault JC, Zucman-Rossi J.

Oncoimmunology. 2013 Dec 1;2(12):e27090. Epub 2014 Jan 3.

42.

Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.

de Reyniès A, Jaurand MC, Renier A, Couchy G, Hysi I, Elarouci N, Galateau-Sallé F, Copin MC, Hofman P, Cazes A, Andujar P, Imbeaud S, Petel F, Pairon JC, Le Pimpec-Barthes F, Zucman-Rossi J, Jean D.

Clin Cancer Res. 2014 Mar 1;20(5):1323-34. doi: 10.1158/1078-0432.CCR-13-2429. Epub 2014 Jan 17.

43.

A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection.

Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J.

Gastroenterology. 2013 Jul;145(1):176-187. doi: 10.1053/j.gastro.2013.03.051. Epub 2013 Apr 6.

PMID:
23567350
44.

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S.

Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548.

45.

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S.

Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20.

PMID:
23421954
46.

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J.

Nat Genet. 2012 May 6;44(6):694-8. doi: 10.1038/ng.2256.

47.

Double heterozygous germline HNF1A mutations in a patient with liver adenomatosis.

Jeannot E, Lacape G, Gin H, Couchy G, Saric J, Laumonier H, Le Bail B, Bioulac-Sage P, Balabaud C, Zucman-Rossi J.

Diabetes Care. 2012 May;35(5):e35. doi: 10.2337/dc12-0030. No abstract available.

48.

KIF20A mRNA and its product MKlp2 are increased during hepatocyte proliferation and hepatocarcinogenesis.

Gasnereau I, Boissan M, Margall-Ducos G, Couchy G, Wendum D, Bourgain-Guglielmetti F, Desdouets C, Lacombe ML, Zucman-Rossi J, Sobczak-Thépot J.

Am J Pathol. 2012 Jan;180(1):131-40. doi: 10.1016/j.ajpath.2011.09.040. Epub 2011 Nov 1.

PMID:
22056911
49.

GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation.

Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J.

J Hepatol. 2012 Jan;56(1):184-91. doi: 10.1016/j.jhep.2011.07.018. Epub 2011 Aug 9.

PMID:
21835143
50.

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas.

Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J.

J Exp Med. 2011 Jul 4;208(7):1359-66. doi: 10.1084/jem.20110283. Epub 2011 Jun 20.

Supplemental Content

Loading ...
Support Center